


Ask a doctor about a prescription for TOLTERODINE NEO NORMON 4 mg PROLONGED-RELEASE HARD CAPSULES
Package Leaflet: Information for the Patient
Tolterodine Neo Normon 4 mg prolonged-release hard capsules EFG
Tolterodine, tartrate
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
The active substance in this medication is tolterodine. Tolterodine belongs to a group of medications called antimuscarinics.
This medication is used to treat the symptoms of overactive bladder syndrome. If you have overactive bladder syndrome, you may notice that:
Do not take Tolterodine Neo Normon
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medication:
Consult your doctor or pharmacist before starting treatment with this medication if you think any of these situations may apply to you.
Other medications and Tolterodine Neo Normon
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
Tolterodine, the active substance in this medication, may interact with other medications.
The use of tolterodine in combination with the following is not recommended:
This medication should be used with caution when administered in combination with:
Taking Tolterodine Neo Normon with food and drinks
This medication can be taken before, during, or after a meal.
Pregnancy and breastfeeding
Pregnancy
Do not use this medication if you are pregnant. Inform your doctor immediately if you are pregnant, think you may be pregnant, or plan to become pregnant.
Breastfeeding
It is unknown whether tolterodine is excreted in breast milk. The use of this medication is not recommended during breastfeeding.
Consult your doctor or pharmacist before using any medication.
Driving and using machines
This medication may make you feel dizzy, tired, or affect your vision. If you experience any of these symptoms, do not drive or operate heavy machinery.
Tolterodine Neo Normon contains lactose and sodium
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per capsule; this is essentially "sodium-free".
Follow the instructions for administration of this medication indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
How to take your Tolterodine Neo Normon capsule:
The prolonged-release hard capsules are taken orally and should be swallowed whole. Do not chew the capsules.
Dose:
Adults:
The usual dose is one 4 mg prolonged-release hard capsule per day.
Liver or kidney disease:
In patients with liver or kidney problems, the doctor may reduce the dose to 2 mg of tolterodine per day.
Use in children:
The use of Tolterodine Neo Normon is not recommended in children.
If you take more Tolterodine Neo Normon than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested. It is recommended to take the package and package leaflet of the medication to the healthcare professional.
The symptoms of an overdose include hallucinations, excitement, accelerated heart rate, dilated pupils, and inability to urinate or breathe normally.
If you forget to take Tolterodine Neo Normon
If you forget to take the dose at the usual time, take it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and continue with the usual schedule.
Do not take a double dose to make up for missed doses.
If you stop taking Tolterodine Neo Normon
Your doctor will indicate the duration of treatment with Tolterodine Neo Normon. Do not stop treatment before because you do not see an immediate effect. Your bladder needs time to adapt to this medication. Complete the treatment with the prolonged-release capsules prescribed by your doctor. If you do not notice any effect, consult your doctor.
The benefit of treatment should be reevaluated after 2-3 months of use. Always consult your doctor if you are thinking of stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them. Some of these effects may be due to the underlying disease.
You should consult your doctor immediately or go to the emergency department if you experience symptoms of angioedema such as:
In addition, you should seek medical attention if you experience a hypersensitivity reaction (e.g., itching, rash, urticaria, and difficulty breathing). This occurs rarely (affects up to 1 in 100 people).
Tell your doctor immediately or go to the emergency department if you experience:
These may be symptoms of heart failure. This occurs rarely (affects up to 1 in 100 people).
The following side effects have been observed during treatment with tolterodine, with the following frequencies:
Very common side effects(may affect more than 1 in 10 people):
Common side effects(may affect up to 1 in 10 people):
Uncommon side effects(may affect up to 1 in 100 people):
Additional reactions reported include severe allergic reactions, confusion, hallucinations, increased heart rate, red skin, stomach burning, vomiting, angioedema, and dry skin and disorientation. Cases of worsening dementia symptoms have been reported in patients being treated for dementia.
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Store below 25°C.
Do not use this medication after the expiration date shown on the package after "EXP". The expiration date is the last day of the month indicated.
The contents of the bottle should be used within 200 days after opening.
Medications should not be disposed of through wastewater or household waste. Deposit the packages and medications you no longer need at the SIGRE collection point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packages and medications you no longer need. This will help protect the environment.
Composition of Tolterodine Neo Normon
The active substance is tolterodine tartrate. Each prolonged-release capsule contains 4 mg of tolterodine tartrate, equivalent to 2.74 mg of tolterodine.
The other components (excipients) of the tablets are: lactose monohydrate, microcrystalline cellulose, polyvinyl acetate, povidone, sodium lauryl sulfate, anhydrous colloidal silica, hypromellose, sodium docusate, magnesium stearate, ethylcellulose, triethyl citrate, methacrylic acid and ethyl acrylate copolymer, propylene glycol.
The other components (excipients) of the capsules are: carmine indigo (E132), titanium dioxide (E171), and gelatin
Appearance of the product and package contents
The 4 mg prolonged-release hard capsules are blue, opaque, size 1, hard gelatin capsules that contain four white, round, and biconvex coated tablets.
Each package contains 28 capsules in blisters or 28 capsules in bottles.
Marketing authorization holder
LABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (SPAIN)
Manufacturer
LABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (SPAIN)
or
PHARMATHEN S.A.
6, Dervenakion Str. - 15351 Pallini Attikis (GREECE)
or
PHARMATHEN INTERNATIONAL
Sapes Industrial Park, Block 5- 69300 Rodopi (GREECE)
Date of the last revision of this package leaflet:February 2025
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
You can access detailed and updated information about this medication by scanning the QR code included in the package leaflet and packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/78266/P_78266.html
The average price of TOLTERODINE NEO NORMON 4 mg PROLONGED-RELEASE HARD CAPSULES in November, 2025 is around 28.58 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TOLTERODINE NEO NORMON 4 mg PROLONGED-RELEASE HARD CAPSULES – subject to medical assessment and local rules.